Wednesday - May 16, 2012

Session IV
Targeting the tumor microenvironment

Chair
Michael Hallek
Department I of Internal Medicine, University of Cologne
Manuel Koch
Institute for Dental Research and Musculoskeletal Biology, University of Cologne

9.00 – 9.35 a.m.
Targeting the tumor vascularization
Roland T. Ullrich
Max Planck Institute for Neurological Research
Department I of Internal Medicine, University of Cologne

9.35 – 10.10 a.m.
Targeting autophagy for cancer treatment
Michael T. Lotze
Department of Surgery, Hillman Cancer Center, University of Pittsburgh

10.10 – 10.45 a.m.
Targeting the innate immunity receptor RIG-I
Gunther Hartmann
Institute of Clinical Chemistry and Pharmacology, University of Bonn

10.45 – 11.15 a.m.
Coffee break

11.15 – 11.50 a.m.
Targeting the natural killer cells
Stephan Gasser
Department of Microbiology, National University of Singapore

11.50 – 12.25 p.m.
Finding more targets within the tumor cell using a functional-genetic approach
Michael T. Hemann
The Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge

12.25 – 1.25 p.m.
Lunch Break

Session V
Inflammation and Cancer

Chair
Karin Hartmann
Department of Dermatology, University of Cologne
Olaf Utermöhlen
Institute of Med Microbiol, Immunol and Hygiene, University of Cologne

1.25 – 2.00 p.m.
Potential of CXCR4 antagonists for cancer treatment
Jan Burger
Department of Leukemia, University of Texas, M. D. Anderson Cancer Center

2.00 – 2.35 p.m.
Reprogramming immune response to improve cytotoxic therapy
Lisa Coussens
Department of Cell & Developmental Biology, Oregon Health and Science University

2.35 – 3.10 p.m.
Targeting cancer-related inflammation
Alberto Mantovani
Istituto Clinico Humanitas, IRCCS, Milan

3.10 – 3.40 p.m.
Coffee break

3.40 – 4.15 p.m.
Monocyte and macrophage diversity in tumor progression and metastasis
Jeffrey W. Pollard
Albert Einstein College of Medicine, New York

4.15 – 4.50 p.m.
IL-6, hepatic inflammation and hepatocellular carcinoma
Thomas Wunderlich
Max Planck Institute for Neurological Research, Cologne

4.50 – 5.25 p.m.
Inflammatory cytokines and autocrine tumor-promoting networkss
Frances Balkwill
Barts and the London, Queen Mary's School of Medicine and Dentistry

5.25 – 5.45 p.m.
Concluding remarks

Venue
Steigenberger Hotel Bad Neuenahr
Conference room „Gartensaal"
Kurgartenstraße 1
53474 Bad Neuenahr

How to find us

Coming from the direction of Aachen/Cologne/Bonn, take the A61 motorway and exit at Bad Neuenahr-Ahrweiler onto the A573 towards Bad Neuenahr.
Coming from the direction of Koblenz and the south, take the exit Sinzig/Bad Neuenahr onto the A571 towards Bad Neuenahr.
In Bad Neuenahr follow the signpost on red hotel route II.



Distance

City center	0 km
Railway station	1 km
Motorway	2 km
Cologne-Bonn airport	55 km

SFB 832 Molecular basis and modulation of cellular interactions in the tumor microenvironment

The tumor microenvironment

an international symposium of SFB 832

May 14 – 16, 2012

Steigenberger Hotel Bad Neuenahr
Germany

Monday - May 14, 2012

11.00 a.m.
Welcome snack

12.00 noon
Welcome address
Michael Hallek
Speaker of the Collaborative Research Center SFB 832

Session I
Genetic instability, DNA damage and oncogenic pathways

Chair
Waldemar Kolanus
Life & Medical Sciences (LIMES) Institute, University of Bonn
Roman Thomas
Translational Genomics, University of Cologne

12.15 – 12.50 p.m.
From translational lung cancer research to translational research of other organ tissues
Sven Perner
Institute of Pathology, University of Bonn

12.50 – 1.25 p.m.
Genomic modifications in CLL
Elias Campo
Department of Pathology, University of Barcelona

1.25 – 2.00 p.m.
DNA damage responses in aging and cancer
Björn Schumacher
Institute for Genetics, CECAD Cologne, University of Cologne

2.00 – 2.30 p.m.
Coffee break

2.30 – 3.05 p.m.
Antagonizing the Hippo pathway in cancer
Bernhard Schermer
Department II of Internal Medicine, University of Cologne

3.05 – 3.40 p.m.
Understanding the DNA damage response – implications for cancer
Jiri Bartek
Center for Genotoxic Stress Research, Danish Cancer Society, Copenhagen

3.40 – 4.15 p.m.
Role of posttranscriptional modification of selective mRNAs in the DNA damage response
Michael Yaffe
Massachusetts Institute of Technology, Cambridge

4.15 – 4.50 p.m.
Exploiting defects in the DNA damage response for targeted cancer therapy
Christian Reinhardt
Department I of Internal Medicine, University of Cologne

4.50 – 5.00 p.m.
Closing remarks

Tuesday - May 15, 2012

Session II
Molecular regulation of cell metabolism, differentiation and cell death in the tumor microenvironment (TME)

Chair
Carien Niessen
Department of Dermatology, University of Cologne
Michael Hoch
Life & Medical Sciences (LIMES) Institute, University of Bonn

9.00 – 9.35 a.m.
Metabolic defects in cancer
Eyal Gottlieb
Apoptosis and Tumor Metabolism Lab
Beaston Inst. for Cancer Research UK, Glasgow

9.35 – 10.10 a.m.
Oxygen metabolism and angiogenesis
Katrien De Bock
Vesalius Research Center, VIB-KULeuven, Belgium

10.10 – 10.45 a.m.
Role of TGFß/Smad signaling in tissue differentiation of human keratinocytes
Petra Boukamp
Division of Genetics of Skin Carcinogenesis,
German Cancer Research Center, Heidelberg

10.45 – 11.15 a.m.
Coffee break

11.15 – 11.50 a.m.
Sensitizing melanoma cells towards the adoptive CTL attack
Hamid Kashkar
Institute of Med Microbiol, Immunol and Hygiene, University of Cologne

11.50 – 12.25 p.m.
Counterintuitive role of CD95 (Fas/Apo-1) as a pro-survival signal in cancer
Seamus J. Martin
Smurfit Institute of Genetics, Trinity College, Dublin

12.25 – 1.00 p.m.
Anti-proliferative role of APRIL antagonists
Jan P. Medema
Lab of Exp. Oncology and Radiobiology,
Academic Medical Center (AMC), Amsterdam

1.00 – 1.35 p.m.
Modeling tumor progression in vitro – ROCK1 inhibition promotes mouse mammary cancer stem cell self-renewal and restricts progression to a mesenchymal tumor initiating cell
Jochen Maurer
Sanford Burnham Medical Research Institute, La Jolla

1.35 – 2.35 p.m.
Lunch Break

Session III
Immune surveillance and the role of distinct immune cells in the TME

Chair
Mirka Uhlirova
Institute for Genetics, CECAD Cologne, University of Cologne
Reinhard Büttner
Institute of Pathology, University of Cologne

2.35 – 3.10 p.m.
Why don't we get more cancer? – The role of the tumor microenvironment in restraining cancer progression
Cyrus Ghajar
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California

3.10 – 3.45 p.m.
Mechanisms of tumor immune escape from NK cell-mediated surveillance
Elke Pogge von Strandmann
Department I of Internal Medicine, University of Cologne

3.45 – 4.20 p.m.
Mechanisms of tumor immune escape from T-cell-mediated immune surveillance
Thomas Tüting
Department of Dermatology and Allergology, University of Bonn

4.20 – 4.45 p.m.
Coffee break

4.45 – 5.20 p.m.
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death
Oliver Kepp
Institut de Cancérologie Gustave Roussy, Villejuif

5.20 – 5.55 p.m.
Insights into reprogramming T regulatory cells
Joachim L. Schultze
Life & Medical Sciences (LIMES) Institute, University of Bonn

5.55 – 6.30 p.m.
A mouse model of Epstein-Barr virus-related lymphoma and immune surveillance against LMP1-expressing B lymphoma cells
Tomoharu Yasuda
Klaus Rajewsky Lab, Max-Delbrück-Zentrum, Berlin